Out of these 4 genes, VEGFA and MDM2 are relatively well-studied effectors of liver cancer, and there are several drugs and drug candidates that are being studied in the context of targeting these proteins as reported in the literature (please see https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL1783 and https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL5023, for VEGFA and MDM2, respectively). The gene discussed is MDM2; the disease is liver cancer.